Literature DB >> 27013743

Incremental value of copeptin in suspected acute myocardial infarction very early after symptom onset.

Fabio Stallone1, Andreas W Schoenenberger2, Christian Puelacher1, Maria Rubini Gimenez1, Brigitte Walz3, Allwin Naduvilekoot Devasia4, Michael Bergner5, Raphael Twerenbold4, Karin Wildi6, Tobias Reichlin4, Petra Hillinger1, Paul Erne7, Christian Mueller8.   

Abstract

BACKGROUND: Patients presenting very early after chest pain onset may provide a diagnostic challenge even when using a high-sensitivity cardiac troponin (hs-cTnT). We hypothesized that in these patients the incremental value of copeptin in the early diagnosis of acute myocardial infarction (AMI) may be substantial.
METHODS: We aimed to investigate the incremental value of copeptin in a pre-specified subgroup analysis of patients presenting with suspected AMI to the emergency department within 2 hours of symptom onset in a multicenter study. Copeptin was measured in a blinded fashion. Two independent cardiologists adjudicated the final diagnosis using all available clinical informations, including high-sensitivity cardiac troponin T (hs-cTnT).
RESULTS: Overall, 2000 patients were enrolled, of whom 519 (26%) arrived within 2 hours of symptom onset. Of these, 102 patients (20%) had an AMI. The additional use of copeptin did not increase diagnostic accuracy as quantified by the area under the receiver-operating characteristic curve (AUC) of hs-cTnT (0.87 (95% confidence interval (CI): 0.83-0.90) for hs-cTnT alone to 0.86 (95% CI: 0.82-0.90) for the combination; p = NS). Copeptin (using 9 pmol/L as a cut-off) increased the negative predictive value (NPV) of hs-cTnT (using 14 ng/L as a cut-off) alone from 93% (95% CI: 90-95%) to 96% (95% CI: 93-98%). The NPV for the combination of hs-cTnT and copeptin was lower in patients arriving in the first 2 hours than in those arriving after 2 hours: 96% (95% CI: 93-98%) versus 99% (95% CI: 99-100%), respectively.
CONCLUSIONS: The additional use of copeptin on top of hs-cTnT seems to lead to a small increase in NPV, but no increase in AUC. Routine use of copeptin in early presenters does not seem warranted. © The European Society of Cardiology 2016.

Entities:  

Keywords:  Acute myocardial infarction; copeptin; early diagnosis; early presenters

Mesh:

Substances:

Year:  2016        PMID: 27013743     DOI: 10.1177/2048872616641289

Source DB:  PubMed          Journal:  Eur Heart J Acute Cardiovasc Care        ISSN: 2048-8726


  9 in total

1.  Early diagnosis of acute myocardial infarction in patients with mild elevations of cardiac troponin.

Authors:  Jasper Boeddinghaus; Tobias Reichlin; Thomas Nestelberger; Raphael Twerenbold; Yvette Meili; Karin Wildi; Petra Hillinger; Maria Rubini Giménez; Janosch Cupa; Lukas Schumacher; Marie Schubera; Patrick Badertscher; Sydney Corbière; Karin Grimm; Christian Puelacher; Zaid Sabti; Dayana Flores Widmer; Nicolas Schaerli; Nikola Kozhuharov; Samyut Shrestha; Tobias Bürge; Patrick Mächler; Michael Büchi; Katharina Rentsch; Òscar Miró; Beatriz López; F Javier Martin-Sanchez; Esther Rodriguez-Adrada; Beata Morawiec; Damian Kawecki; Eva Ganovská; Jiri Parenica; Jens Lohrmann; Andreas Buser; Dagmar I Keller; Stefan Osswald; Christian Mueller
Journal:  Clin Res Cardiol       Date:  2017-02-01       Impact factor: 5.460

Review 2.  Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases.

Authors:  Danni Mu; Jin Cheng; Ling Qiu; Xinqi Cheng
Journal:  Front Cardiovasc Med       Date:  2022-07-04

3.  Improving the ACS Triage-Using High Sensitivity TroponinI and Copeptin for Early 'Rule-Out' of AMI.

Authors:  M Kankra; A Mehta; J P S Sawhney; S Solanki; S Bhargava; A Ahirwar; A Manocha; P Singla; A Sharma; M Sharma
Journal:  Indian J Clin Biochem       Date:  2022-01-08

4.  Prohormones in the Early Diagnosis of Cardiac Syncope.

Authors:  Patrick Badertscher; Thomas Nestelberger; Jeanne du Fay de Lavallaz; Martin Than; Beata Morawiec; Damian Kawecki; Òscar Miró; Beatriz López; F Javier Martin-Sanchez; José Bustamante; Nicolas Geigy; Michael Christ; Salvatore Di Somma; W Frank Peacock; Louise Cullen; François Sarasin; Dayana Flores; Michael Tschuck; Jasper Boeddinghaus; Raphael Twerenbold; Karin Wildi; Zaid Sabti; Christian Puelacher; Maria Rubini Giménez; Nikola Kozhuharov; Samyut Shrestha; Ivo Strebel; Katharina Rentsch; Dagmar I Keller; Imke Poepping; Andreas Buser; Wanda Kloos; Jens Lohrmann; Michael Kuehne; Stefan Osswald; Tobias Reichlin; Christian Mueller
Journal:  J Am Heart Assoc       Date:  2017-12-14       Impact factor: 5.501

5.  Is high-sensitivity troponin, alone or in combination with copeptin, sensitive enough for ruling out NSTEMI in very early presenters at admission? A post hoc analysis performed in emergency departments.

Authors:  Camille Chenevier-Gobeaux; Mustapha Sebbane; Christophe Meune; Sophie Lefebvre; Anne-Marie Dupuy; Guillaume Lefèvre; Nicolas Peschanski; Patrick Ray
Journal:  BMJ Open       Date:  2019-06-16       Impact factor: 2.692

6.  Adding stress biomarkers to high-sensitivity cardiac troponin for rapid non-ST-elevation myocardial infarction rule-out protocols.

Authors:  Ingar Ziad Restan; Ana Yufera Sanchez; Ole-Thomas Steiro; Pedro Lopez-Ayala; Hilde L Tjora; Jørund Langørgen; Torbjørn Omland; Jasper Boeddinghaus; Thomas Nestelberger; Luca Koechlin; Paul Collinson; Rune Bjørneklett; Kjell Vikenes; Heidi Strand; Øyvind Skadberg; Øistein R Mjelva; Alf Inge Larsen; Vernon V S Bonarjee; Christian Mueller; Kristin M Aakre
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2022-03-16

Review 7.  Performance of Copeptin for Early Diagnosis of Acute Coronary Syndromes: A Systematic Review and Meta-Analysis of 14,139 Patients.

Authors:  Lukasz Szarpak; Marcin Lapinski; Aleksandra Gasecka; Michal Pruc; Wiktoria L Drela; Mariusz Koda; Andrea Denegri; Frank W Peacock; Miłosz J Jaguszewski; Krzysztof J Filipiak
Journal:  J Cardiovasc Dev Dis       Date:  2021-12-27

8.  Biomarkers-in-Cardiology 8 RE-VISITED-Consistent Safety of Early Discharge with a Dual Marker Strategy Combining a Normal hs-cTnT with a Normal Copeptin in Low-to-Intermediate Risk Patients with Suspected Acute Coronary Syndrome-A Secondary Analysis of the Randomized Biomarkers-in-Cardiology 8 Trial.

Authors:  Evangelos Giannitsis; Tania Garfias-Veitl; Anna Slagman; Julia Searle; Christian Müller; Stefan Blankenberg; Stephan von Haehling; Hugo A Katus; Christian W Hamm; Kurt Huber; Jörn O Vollert; Martin Möckel
Journal:  Cells       Date:  2022-01-08       Impact factor: 6.600

9.  Critical appraisal of the 2020 ESC guideline recommendations on diagnosis and risk assessment in patients with suspected non-ST-segment elevation acute coronary syndrome.

Authors:  Evangelos Giannitsis; Stefan Blankenberg; Robert H Christenson; Norbert Frey; Stephan von Haehling; Christian W Hamm; Kenji Inoue; Hugo A Katus; Chien-Chang Lee; James McCord; Martin Möckel; Jack Tan Wei Chieh; Marco Tubaro; Kai C Wollert; Kurt Huber
Journal:  Clin Res Cardiol       Date:  2021-02-26       Impact factor: 5.460

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.